focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.75
Bid: 0.70
Ask: 0.80
Change: 0.00 (0.00%)
Spread: 0.10 (14.286%)
Open: 0.75
High: 0.75
Low: 0.75
Prev. Close: 0.75
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

N4 Pharma shares surge on latest from Nanomerics collaboration

Thu, 03rd Dec 2020 13:39

(Sharecast News) - Specialist pharmaceuticals company N4 Pharma updated the market on its ongoing research collaboration agreement with Nanomerics on Thursday.
The AIM-traded firm had initiated the first phase of research to test the stability of different formulations of 'Nuvec' loaded with a well-characterised plasmid DNA, as it announced in February.

It reported on Thursday that, in addition to not degrading the plasmid DNA, Nuvec formulations that had been freeze dried and stored for 14 days either at room temperature or at four degrees Celsius, showed "no significant drop" in in-vitro transfection capability following reconstitution compared to fresh formulations.

In parallel to continued work on analysing stability duration, N4 said different formulations would now be chosen to move forward into the second phase of the work programme, testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model.

"Demonstrating that Nuvec® loaded with a plasmid DNA can be dried, stored at convenient temperatures and reconstituted without any drop in transfection is a significant step forward in our formulation development work," said chief executive officer Nigel Theobald.

"The recent success of Pfizer and Moderna with an mRNA Covid-19 vaccine shows the potential for nucleic acid vaccines.

"However, it also highlights that these vaccines have certain limitations, in that they often require extreme storage conditions."

Theobald said that, although vaccine efficacy was primarily determined by the selected nucleic acid antigen, having a stable, easy-to-store and easy-to-use vaccine was "crucial" in helping vaccine acceptance and uptake.

"A formulation stable at room temperature or even refrigerated can represent significant cost savings in vaccine transportation, storage and administration.

"We believe, to the extent that Nuvec as a delivery platform can provide a solution in this area, it could be of significant interest to multiple vaccine developers.

"Work will continue in this area and will add to the breadth of proof of concept data we are building for the use of Nuvec® as a delivery system for vaccines and cancer treatments."

At 1237 GMT, shares in N4 Pharma were up 40% at 8.4p.
More News
27 Mar 2023 15:50

UK earnings, trading statements calendar - next 7 days

Tuesday 28 March 
AG Barr PLCFull Year Results
Animalcare Group PLCFull Year Results
Bango PLCTrading Statement
Bellway PLCHalf Year Results
CPPGroup PLCFull Year Results
DigitalBox PLCFull Year Results
eEnergy Group PLCHalf Year Results
EKF Diagnostics Holdings PLCFull Year Results
Eleco PLCFull Year Results
Empresaria Group PLCFull Year Results
Flowtech Fluidpower PLCFull Year Results
Good Energy Group PLCFull Year Results
Impact Healthcare REIT PLCFull Year Results
John Wood Group PLCFull Year Results
Marlowe PLCTrading Statement
Mission Group PLCFull Year Results
Mortgage Advice Bureau Holdings PLCFull Year Results
Nanoco Group PLCHalf Year Results
Ocado Group PLCTrading Statement
Personal Group Holdings PLCFull Year Results
Petershill Partners PLCFull Year Results
Real Estate Investors PLCFull Year Results
Regional REIT LtdFull Year Results
S&U PLCFull Year Results
Softcat PLCHalf Year Results
Synthomer PLCFull Year Results
Team17 Group PLCFull Year Results
United Utilities Group PLCTrading Statement
VH Global Sustainable Energy Opportunities PLCFull Year Results
Xaar PLCFull Year Results
Wednesday 29 March 
abrdn Smaller Companies Income Trust PLCFull Year Results
Artisanal Spirits Co PLCFull Year Results
Baillie Gifford Japan Trust PLCHalf Year Results
Big Technologies PLCFull Year Results
Bowleven PLCHalf Year Results
Central Asia Metals PLCFull Year Results
Ecora Resources PLCFull Year Results
Essentra PLCFull Year Results
Highcroft Investments PLCFull Year Results
Inspired PLCFull Year Results
Medica Group PLCFull Year Results
Michelmersh Brick Holdings PLCFull Year Results
Next PLCFull Year Results
Octopus Renewable Infrastructure Trust PLCFull Year Results
OPG Power Ventures PLCTrading Statement
RM PLCFull Year Results
S4 Capital PLCFull Year Results
Strix Group PLCFull Year Results
Surgical Innovations Group PLCFull Year Results
tinyBuild IncFull Year Results
UP Global Sourcing Holdings PLCHalf Year Results
Thursday 30 March 
AO World PLCTrading Statement
Aquis Exchange PLCFull Year Results
Arbuthnot Banking Group PLCFull Year Results
Ascential PLCFull Year Results
BBGI Global Infrastructure SAFull Year Results
Chesnara PLCFull Year Results
Ebiquity PLCFull Year Results
Gattaca PLCHalf Year Results
Gresham House PLCFull Year Results
IGas Energy PLCFull Year Results
Impellam Group PLCFull Year Results
International Public Partnerships LtdFull Year Results
Ithaca Energy PLCFull Year Results
Microlise Group PLCFull Year Results
Moonpig Group PLCTrading Statement
PetroTal CorpFull Year Results
Renalytix PLCHalf Year Results
Revolution Beauty Group PLCFull Year Results
Robinson PLCFull Year Results
Secure Trust Bank PLCFull Year Results
Supermarket Income REIT PLCHalf Year Results
XLMedia PLCFull Year Results
Friday 31 March 
Bank of Cyprus Holdings PLCFull Year Results
Computacenter PLCFull Year Results
Cooks Coffee Co LtdFull Year Results
CT Private Equity Trust PLCFull Year Results
Dignity PLCFull Year Results
ECO Animal Health Group PLCTrading Statement
HealthBeacon PLCFull Year Results
Impax Environmental Markets PLCFull Year Results
James Halstead PLCHalf Year Results
Jaywing PLCTrading Statement
JPMorgan American Investment Trust PLCFull Year Results
Numis Corp PLCTrading Statement
Mothercare PLCTrading Statement
Quarto Group IncFull Year Results
UK Oil & Gas PLCFull Year Results
Vanquis Banking Group PLCFull Year Results
Monday 3 April 
Downing Renewables & Infrastructure Trust PLCFull Year Results
Elixirr International PLCFull Year Results
Fidelity Japan Trust PLCFull Year Results
Gaming Realms PLCFull Year Results
HydrogenOne Capital Growth PLCFull Year Results
N4 Pharma PLCFull Year Results
Renew Holdings PLCTrading Statement
Tracsis PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
9 Mar 2023 14:32

EARNINGS SUMMARY: Franchise Brands blooms; Tlou Energy loss widens

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
17 Jan 2023 16:23

TRADING UPDATES: hVIVO wins contract; Dev Clever cancels shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
18 Nov 2022 11:16

AIM WINNERS & LOSERS: Parsley Box to exit AIM as shares wilt since IPO

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
18 Nov 2022 11:02

N4 Pharma plummets on broker offer to raise up to GBP1 million

(Alliance News) - N4 Pharma PLC shares plummeted on Friday, after it raised GBP1.0 million through a placing of 50.0 million shares and announced a broker offer to raise up to GBP1.0 million.

Read more
18 Nov 2022 08:11

N4 Pharma shares tumble following placing, broker offer announcement

(Sharecast News) - Shares in pharmaceutical company N4 Pharma tumbled on Friday after the group said it had raised £1.0m via the placing of 50.0m new ordinary shares of 0.4p each and detailed a broker offer aimed at raising as much as another £1.0m.

Read more
1 Nov 2022 17:06

IN BRIEF: N4 Pharma expands patent application claims for Nuvec

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Provides a patent application update for Nuvec.

Read more
4 Oct 2022 13:32

N4 Pharma reports success in recent 'Nuvec' testing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma announced success in its in-vitro testing of its 'Nuvec' drug delivery system on Tuesday, loaded with two small interfering RNA (siRNA) probes.

Read more
4 Oct 2022 11:19

AIM WINNERS & LOSERS: N4's Nuvec success; Watkin Jones tumbles

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
4 Oct 2022 10:38

N4 Pharma announces successful test in next stage of Nuvec development

(Alliance News) - N4 Pharma PLC on Tuesday announced successful in vitro testing of Nuvec when loaded with two small interfering siRNA probes.

Read more
4 Oct 2022 08:46

LONDON MARKET OPEN: Stocks rise as market sentiment recovers

(Alliance News) - Stock prices in London opened sharply higher on Tuesday, lifted by more positive market sentiment following the UK government's tax U-turn, as well as some positive trading updates.

Read more
29 Sep 2022 15:09

EARNINGS UPDATES: Crestchic raises outlook on record year-to-date

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Sep 2022 12:11

N4 Pharma reduces losses as Nuvec development continues

(Sharecast News) - Specialist pharmaceutical company N4 Pharma reduced its operating loss in the first half, it reported on Thursday, to £0.75m from £0.97m a year earlier.

Read more
14 Sep 2022 12:03

IN BRIEF: N4 completes testing on loading Nuvec drug with siRNA probes

N4 Pharma PLC - Derbyshire, England-based pharmaceutical company - Completes initial testing on loading its Nuvec treatment with two generic siRNA probes at the same time. siRNA can prevent cells from communicating, potentially preventing cancer cells from replicating. N4 are now undertaking experiments using siRNA sequences against known oncology targets. This includes in vitro using a lung cancer cell line and, after that, in vivo studies in mice. Chief Executive Officer Nigel Theobald said: "We have now identified a very strong commercial point of difference for Nuvec in that it can be successfully loaded with at least two siRNA genes".

Read more
15 Jul 2022 21:26

TRADING UPDATES: Premier Miton assets dip; Challenger Energy CFO quits

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.